A Qualitative Study on Female Resident Assistants & Perceived Stress

Researchers have shown female college students tend to experience stress more often than their male counterparts. However, there is little research regarding female resident assistants and their experiences with stress. In this qualitative study I focused on how female resident assistants perceive stress in their lives. The study was conducted at a small, private, evangelical institution in the Midwest and was guided by four research questions relating to how stress unique to this student leadership role impacts overall student success and well-being. In this study I found female resident assistants do experience stress in a variety of ways, both related and unrelated to being a resident assistant, but are generally able to balance their leadership role with all other areas of their lives

The Grizzly, October 22, 2015

New President on the Brock: Brock Blomberg Takes the Helm at Ursinus • Blomberg Installed as 17th President • Blomberg Begins New Era with Intellectual Discussions • Homecoming Court Crowned • 5 Questions with Brock • A Historic Moment Celebrated in a Historic Place • A Taste of the Workplace • Dr. Hess has Good Chemistry with Freshmen Students • Opinions: Should UC Ban Cigarettes?; New Film Green Inferno Rates 3 / 10 • Distance Doesn\u27t Matter: Two Women\u27s Soccer Players Come From Very Far Apart • Men\u27s and Women\u27s Soccer Look to End Seasons on a High Notehttps://digitalcommons.ursinus.edu/grizzlynews/1674/thumbnail.jp

The Grizzly, October 29, 2015

SPINT Hosts Trick-or-Treating • Fall Foliage at Ursinus • Antisemitism Panel Seeks Nuance • HEART Lab Brings Promising Results • Harvest Festival Ends Sustainability Week • Rekindling the Lantern • A Poem a Day Keeps Writer\u27s Block Away • In the Voice of the Frog • Opinions: Voter Ambivalence is Harmful; Gun Control a Loaded Issue • Division III Sports Offer Big-Time Benefits to Ursinus Athletes • Men\u27s and Women\u27s Swimming Prepare for Start of Seasonhttps://digitalcommons.ursinus.edu/grizzlynews/1675/thumbnail.jp

The Grizzly, September 10, 2015

Campus Adapts to Canvas Roll Out • Blomberg Spends Summer Traveling, Meeting with Alumni • New Greek Organizations Look to Form Chapters on Campus • Student Government Launches Free Textbook Pilot Program • Ursinus Songwriter Explores Human Nature Through Music • Mentors in Academics and Life: Ursinus Remembers Dr. Cameron and Dr. Hemphill • Theater Community Welcomes Performing Arts Scholar • Opinions: New Tips for a New Year at UC; Straight Outta Compton Rates 7 / 10 • Globetrotters: Men\u27s Basketball Competes in Europe • Bears Upset Millersville in Record Five Overtimeshttps://digitalcommons.ursinus.edu/grizzlynews/1669/thumbnail.jp

The Grizzly, November 12, 2015

Highlighting a New Trend on Campus • Making Connections: Ursinus Prepares to Break Ground on a Structure Between Pfahler and Thomas • Acclaimed Literary Critic to Give Talk on Campus • Ursinus Brings Top Lawyer Aboard in New Position • International Perspective: How One Student Uses Dance to Connect Ethiopia and Ursinus • Can You Really Netflix and Chill Without Killing Your Grades? • Opinions: Are You a White Feminist?; Bridge of Spies • Defensive Lineman Unleashes Passion for Music • Field Hockey Upsets F&M for Titlehttps://digitalcommons.ursinus.edu/grizzlynews/1677/thumbnail.jp

Amplified Loci on Chromosomes 8 and 17 Predict Early Relapse in ER-Positive Breast Cancers

Adjuvant hormonal therapy is administered to all early stage ER+ breast cancers, and has led to significantly improved survival. Unfortunately, a subset of ER+ breast cancers suffer early relapse despite hormonal therapy. To identify molecular markers associated with early relapse in ER+ breast cancer, an outlier analysis method was applied to a published gene expression dataset of 268 ER+ early-stage breast cancers treated with tamoxifen alone. Increased expression of sets of genes that clustered in chromosomal locations consistent with the presence of amplicons at 8q24.3, 8p11.2, 17q12 (HER2 locus) and 17q21.33-q25.1 were each found to be independent markers for early disease recurrence. Distant metastasis free survival (DMFS) after 10 years for cases with any amplicon (DMFS  = 56.1%, 95% CI  = 48.3–63.9%) was significantly lower (P  = 0.0016) than cases without any of the amplicons (DMFS  = 87%, 95% CI  = 76.3% –97.7%). The association between presence of chromosomal amplifications in these regions and poor outcome in ER+ breast cancers was independent of histologic grade and was confirmed in independent clinical datasets. A separate validation using a FISH-based assay to detect the amplicons at 8q24.3, 8p11.2, and 17q21.33-q25.1 in a set of 36 early stage ER+/HER2- breast cancers treated with tamoxifen suggests that the presence of these amplicons are indeed predictive of early recurrence. We conclude that these amplicons may serve as prognostic markers of early relapse in ER+ breast cancer, and may identify novel therapeutic targets for poor prognosis ER+ breast cancers

The James Webb Space Telescope Mission

Twenty-six years ago a small committee report, building on earlier studies, expounded a compelling and poetic vision for the future of astronomy, calling for an infrared-optimized space telescope with an aperture of at least $4m$. With the support of their governments in the US, Europe, and Canada, 20,000 people realized that vision as the $6.5m$ James Webb Space Telescope. A generation of astronomers will celebrate their accomplishments for the life of the mission, potentially as long as 20 years, and beyond. This report and the scientific discoveries that follow are extended thank-you notes to the 20,000 team members. The telescope is working perfectly, with much better image quality than expected. In this and accompanying papers, we give a brief history, describe the observatory, outline its objectives and current observing program, and discuss the inventions and people who made it possible. We cite detailed reports on the design and the measured performance on orbit.Comment: Accepted by PASP for the special issue on The James Webb Space Telescope Overview, 29 pages, 4 figure

Finishing the euchromatic sequence of the human genome

The sequence of the human genome encodes the genetic instructions for human physiology, as well as rich information about human evolution. In 2001, the International Human Genome Sequencing Consortium reported a draft sequence of the euchromatic portion of the human genome. Since then, the international collaboration has worked to convert this draft into a genome sequence with high accuracy and nearly complete coverage. Here, we report the result of this finishing process. The current genome sequence (Build 35) contains 2.85 billion nucleotides interrupted by only 341 gaps. It covers ∼99% of the euchromatic genome and is accurate to an error rate of ∼1 event per 100,000 bases. Many of the remaining euchromatic gaps are associated with segmental duplications and will require focused work with new methods. The near-complete sequence, the first for a vertebrate, greatly improves the precision of biological analyses of the human genome including studies of gene number, birth and death. Notably, the human enome seems to encode only 20,000-25,000 protein-coding genes. The genome sequence reported here should serve as a firm foundation for biomedical research in the decades ahead

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570